Clinical trial

Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

Recruiting now · Not applicable · 1 countries · Registry ID NCT05498675

Recruiting nowNot applicableObservational

What this study is about

The purpose of this study is to investigate the effect of sacubitril/valsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 70 Years

SexAll

Healthy volunteersNot accepted

ConditionSacubitril/Valsartan, Hypertension, Obesity

Full registry criteria

Inclusion Criteria: * Patients with essential hypertension * 18-70 years old * No major barriers to provide written consent Exclusion Criteria: * Secondary hypertension, except because of sleep apnea * cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months * Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases) * Unable to understand or comply with the study procedures

Treatments and study arms

Sacubitril / Valsartan Oral Tablet [Entresto]

Drug

There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.

ACEI/ARB

Drug

There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group. Including: benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan.

Primary outcomes

Changes on left ventricular ejection fraction (LVEF)6 months

Changes on LVEF in % assessed with the use of cardiac magnetic resonance (CMR).

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Beijing Friendship Hospital, Capital Medical University🇨🇳 Beijing, Beijing Municipality, China

Open map

Rongchong Huang, M.D.Contact

Email · Call +86-13811039417

Rongchong Huang, M.D.Principal Investigator